TY - GEN
T1 - Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost, mass spectrometry-based DNA methylomics
AU - Schwalbe, E.C.
AU - Gohlke, H.
AU - Hicks, D.
AU - Rafiee, Gholamreza
AU - Enshaei, A
AU - Potluri, S.
AU - Matthiesen, J.
AU - Mather, M.
AU - Chaston, R
AU - Crosier, S.
AU - Smith, A. J.
AU - Williamson, D.
AU - Bailey, S.
AU - Clifford, S.C.
PY - 2014
Y1 - 2014
N2 - DNA-methylation patterns allow the subclassification of medulloblastoma, the most common childhood malignant brain tumour, into four molecular subgroups (WNT, SHH, MBGrp3 and MBGrp4). These subgroups have distinct molecular and clinico-pathological features, and their distinction is now informing future treatments and risk-stratification. Whilst microarrays to assign subgroup are suitable for research purposes, they are limited by expense, platform-specificity, sample quality requirements and practicality. Here, we aimed to develop a low-cost, array-independent, robust subgrouping assay suitable for routine quality-controlled subclassification, including scant and poor-quality samples.
AB - DNA-methylation patterns allow the subclassification of medulloblastoma, the most common childhood malignant brain tumour, into four molecular subgroups (WNT, SHH, MBGrp3 and MBGrp4). These subgroups have distinct molecular and clinico-pathological features, and their distinction is now informing future treatments and risk-stratification. Whilst microarrays to assign subgroup are suitable for research purposes, they are limited by expense, platform-specificity, sample quality requirements and practicality. Here, we aimed to develop a low-cost, array-independent, robust subgrouping assay suitable for routine quality-controlled subclassification, including scant and poor-quality samples.
M3 - Other contribution
PB - National Cancer Research Institute (NCRI)
ER -